4.7 Review

Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor

Journal

BIOMOLECULES
Volume 11, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/biom11010063

Keywords

nanobodies; cell plasma membrane transport proteins; drug target; therapy

Funding

  1. European Research Council [861913]
  2. Research Foundation Flanders-Belgium (FWO) [G012318N, G020018N, G0F7219N]
  3. University Hospital of the Vrije Universiteit Brussel-Belgium (Scientific Fund Willy Gepts)
  4. European Research Council (ERC) [861913] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Cell plasma membrane proteins play a crucial role in cell regulation, with transport proteins facilitating molecule and ion exchange. The dysfunction of these proteins can lead to various human pathologies, making them potential therapeutic targets. Nanobodies show promise in targeting and modulating the activity of these proteins, offering a potential approach in drug development.
Cell plasma membrane proteins are considered as gatekeepers of the cell and play a major role in regulating various processes. Transport proteins constitute a subclass of cell plasma membrane proteins enabling the exchange of molecules and ions between the extracellular environment and the cytosol. A plethora of human pathologies are associated with the altered expression or dysfunction of cell plasma membrane transport proteins, making them interesting therapeutic drug targets. However, the search for therapeutics is challenging, since many drug candidates targeting cell plasma membrane proteins fail in (pre)clinical testing due to inadequate selectivity, specificity, potency or stability. These latter characteristics are met by nanobodies, which potentially renders them eligible therapeutics targeting cell plasma membrane proteins. Therefore, a therapeutic nanobody-based strategy seems a valid approach to target and modulate the activity of cell plasma membrane transport proteins. This review paper focuses on methodologies to generate cell plasma membrane transport protein-targeting nanobodies, and the advantages and pitfalls while generating these small antibody-derivatives, and discusses several therapeutic nanobodies directed towards transmembrane proteins, including channels and pores, adenosine triphosphate-powered pumps and porters.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available